MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Available at Chicago Ridge, Orland Park
A phase IIIb study to characterize the efficacy and safety of ADJUVANT ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (ADJUVANT WIDER) (CLEE011O12001)
Available at Chicago Ridge, Orland Park
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%.
Available at Chicago Ridge, Orland Park
A phase 3, randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, Kras G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer (co45042).
Available at Chicago Ridge, Orland Park
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants with Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Available at Chicago Ridge, Orland Park
If you are interested in learning more about our cancer research program, you can read frequently asked questions about clinical trials answered by the cancer research specialists at Affiliated Oncologists.
To find out more about a clinical trial listed here and if you are eligible for participation, you can call or request an appointment at the Affiliated Oncologists location where the trial is available, including Chicago Ridge and Orland Park.
